Indiana

Global health R&D delivers for Indiana

Click here to select a new state

Select a new state

US government investment in global health R&D has delivered

$192.9 million

to Indiana research institutions

2,400+ new jobs

for Indiana

Indiana's top USG-funded global health R&D institutions

Indiana University-Purdue University Indianapolis

$58.2 million

University of Notre Dame

$54.1 million

Purdue University

$33.9 million

Envigo*

$28.5 million

Indiana University Bloomington

$11.7 million

Regenstrief Institute

$4.7 million

Butler University

$378 thousand

Aarden Pharmaceuticals Inc.*

$313 thousand

Kovina Therapeutics Inc.

$299 thousand

Earlham College

$269 thousand

Lgenia Inc.

$255 thousand

Cummins Technical Center

$227 thousand

Marian University

$76 thousand

Indiana's top areas of global health R&D by USG funding

20.2%

COVID-19

5.4%

Flioviral diseases (including Ebola, Marburg)

13%

HIV/AIDS

23.8%

Malaria

8.9%

Neglected tropical diseases

Dengue

Helminth infections (Worms & Flukes)

Kinetoplastid diseases

6.4%

Reproductive health

12.4%

Tuberculosis

10%

Other

Arenaviral hemorrhagic fevers (including Lassa fever)

Bacterial pneumonia & meningitis

Bunyaviral diseases (including CCHF, RVF, SFTS)

Chikungunya

Diarrheal diseases

Emergent non-polio enteroviruses (including EV71, D68)

Hepatitis B

Multi-disease/health area R&D

Salmonella infections

Zika

Neglected and emerging diseases in Indiana

Chikungunya cases

Dengue cases

HIV diagnoses

569

Malaria cases

Mpox cases

Tuberculosis cases

176

Global health R&D at work in Indiana

Researchers from the University of Notre Dame are conducting clinical trials to test the effectiveness of spatial repellents in preventing mosquito-borne diseases, including dengue and malaria. Spatial repellents release chemicals (a common example is a mosquito candle) that can help stop the spread of disease where existing tools, such as bednets and indoor residual spraying, are not entirely effective. New strategies are needed to avert the estimated 390 million cases of dengue and 247 million cases of malaria that occur each year globally. The project will generate data to inform disease control programs.

Footnotes

Methodology
US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
*Organization appears to be closed/out of business.
Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
Case study photo: Peace Corps